International Latest

UK drugmaker confirms COVID-19 vaccine achieved 70% efficacy during clinical trials

Research results by the British drugs group AstraZeneca and the University of Oxford has revealed that their jointly-developed COVID-19 vaccine has shown “an average 70 percent efficacy during trials.

AstraZeneca Chief Executive, Pascal Soriot, disclosed this in a statement on Monday.

“This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency.”

The United Kingdom group is the latest drugmaker to unveil positive interim data in a scientific race to curb a global pandemic with results ranging between 62 and 90-percent efficacy, depending on the vaccine dosage.

READ ALSO: COVID-19: AstraZeneca resumes UK vaccine trials

“Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19 and no hospitalisations or severe cases of the disease were reported in participants.

“One dosing regimen (n=2,741) showed vaccine efficacy of 90 percent when AZD1222 was given as a half dose, followed by a full dose at least one month apart,” the company’s chief added.

Join the conversation


About the author

Ripples Nigeria

We are an online newspaper, very passionate about Nigerian politics, business and their leaders. We dig deeper, without borders and without fears.

/* ]]> */